Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience
CAP TODAY does not endorse any of the products or services named within. The roundtable is made possible by a special educational grant from Tosoh Bioscience Inc.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from OncoLens and Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The roundtable is made possible by a special educational grant from Pillar Biosciences.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.
Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Illumina.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
April 2015—The Binding Site, through its arrangement with Arotec Diagnostics, offers an Ro (SSA) antigen designed for use as a component in solid phase ELISA-based immunoassay test procedures for the detection of anti-Ro (SSA) antibodies for use in research and in vitro diagnostic manufacturing applications.
April 2015—Genologics announced that GenomeDx Biosciences has implemented Genologics’ laboratory information management system, Clarity LIMS, to support whole transcriptome analysis workflows as part of GenomeDx’s mission to address unmet clinical needs in the management of prostate cancer. Headquartered in Vancouver, BC, GenomeDx will use Clarity LIMS in its CLIA-certified lab in San Diego.
April 2015—The NanoZoomer-SQ from Hamamatsu is a compact, single slide desktop scanner that converts a glass slide into a high-resolution digital image.
April 2015—The Clinical and Laboratory Standards Institute has published “Quality System Regulation for Laboratory-Developed Tests: A Practical Guide for the Laboratory.” The guide is intended to clarify how to implement the Quality System Regulation, 21 CFR 820, that may be required for some classifications of LDTs.
April 2015—Beckman Coulter Genomics has added stranded, ribodepletion and globin reduction library construction options to its existing RNA-Seq services. The Illumina TruSeq Stranded Total RNA Sample Prep Kit has been validated at Beckman Coulter Genomics for human, mouse, rat, and plant samples and automated on Beckman Coulter instruments to enable scalability and LIMS sample tracking. In addition, it includes the ability to work with samples derived from blood and formalin-fixed, paraffin-embedded tissue.
April 2015—In an exclusive arrangement with Arotec Diagnostics, the Binding Site has added five antibodies to its line of in vitro diagnostic manufacturing and research products: Anti-NGAL, Anti-Calprotectin, Anti-Azurocidin, Anti-Neutrophil Elastase, and Anti-Neutrophil Lactoferrin.
April 2015—This special formulation of Vector Labs’ VectaShield HardSet Mounting Medium, which prevents photobleaching of fluorescent proteins and fluorescent dyes, contains TRITC-phalloidin. Phalloidin is a bicyclic heptapeptide that specifically binds actin filaments within a cell.
April 2015—Dako, an Agilent Technologies company, and Ono Pharmaceutical announced a partnership to develop a potential diagnostic test specifically for use with Opdivo in the treatment of non-small cell lung cancer.
March 2015—Illumina launched the MiSeq FGx Forensic Genomics System, a fully validated forensic next-generation sequencing system that simultaneously interrogates short tandem repeats and other valuable genetic markers, including single nucleotide polymorphisms, to provide informative DNA profiles. The system enables robust analysis of a range of genetic markers in a single workflow.
March 2015—Dako, an Agilent Technologies company, and Cell Signaling Technology have entered into a strategic partnership to supply antibodies for use in Dako-branded companion diagnostics products.
